When an FDA advisory comes together you have some of the top experts in the country debating the merits. 16-2 is a resounding defeat for those wanting to roll out the booster to young people. ""While I would probably support a three-dose recommendation for those over 60 or 65, I really have trouble supporting this as written for anyone of greater than or equal to 16," said Paul Offit of the Children's Hospital of Philadelphia. Others focused on the clear lack of data on the booster's safety in young people, especially 16- and 17-year-olds. “We have no data on the safety for this population at all," Chatterjee said. That will probably not stop HC pharma shills calling for it, or the FDA approving it.
